Please use this identifier to cite or link to this item:
|Title:||Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort|
|Author:||Fortner, Renée T.|
Bueno de Mesquita, H. Bas
Peeters, Petra H. M.
van Gils, Carla H.
Quirós, J. Ramón
Sánchez, María José
Chirlaque, María Dolores
Merritt, Melissa A.
|Keywords:||Càncer de mama|
|Abstract:||Background: Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and breast cancer risk has been examined in only one prior study. Methods: A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 2008 incident invasive breast cancer cases (estrogen receptor (ER)+, n = 1622; ER-, n = 386), matched 1: 1 to controls, were included in the analysis. Women were predominantly postmenopausal at blood collection (77%); postmenopausal women included users and non-users of postmenopausal hormone therapy (HT). Serum OPG was quantified with an electrochemiluminescence assay. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression. Results: The associations between OPG and ER+ and ER-breast cancer differed significantly. Higher concentrations of OPG were associated with increased risk of ER-breast cancer (top vs. bottom tertile RR = 1.93 [95% CI 1.24-3.02]; p(trend) = 0.03). We observed a suggestive inverse association for ER+ disease overall and among women premenopausal at blood collection. Results for ER-disease did not differ by menopausal status at blood collection (p(het) = 0.97), and we observed no heterogeneity by HT use at blood collection (p(het) >= 0.43) or age at breast cancer diagnosis (p(het) >= 0.30). Conclusions: This study provides the first prospective data on OPG and breast cancer risk by hormone receptor subtype. High circulating OPG may represent a novel risk factor for ER-breast cancer.|
|Note:||Reproducció del document publicat a: https://doi.org/10.1186/s12916-017-0786-8|
|It is part of:||BMC Medicine, 2017, vol. 15, num. 26|
|Appears in Collections:||Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))|
This item is licensed under a Creative Commons License